Aleksandar F. Dragovic

Aleksandar F. Dragovic

Auto-generated profile, based on publicly available information

Aleksandar F. Dragovic

Department of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PSPaul L. Swiecicki
Paul L. Swiecicki
EBEmily Bellile
Emily Bellile
ADAleksandar F. Dragovic
Aleksandar F. Dragovic
JMJonathan McHugh
Jonathan McHugh
AUAaron Udager
Aaron Udager
MSMatthew E. Spector
Matthew E. Spector
Purpose: Locoregionally advanced HPV+ oropharyngeal squamous cell carcinoma (OPSCC) has excellent cure rates, although current treatment regimens are accompanied by acute and long-term toxicities. We designed a phase II deescalation trial for patients with HPV+ OPSCC to evaluate the feasibility of an upfront neck dissection to individualize definitive treatment selection to improve the quality of life without compromising survival. Patients and Methods: Patients with T1–3, N0–2 HPV+ OPSCC underwent an upfront neck dissection with primary tumor biopsy. Arm A included patients with a single lymph node less than six centimeters, with no extracapsular spread (ECS) and no primary site adverse features underwent transoral surgery. Arm B included patients who had two or more positive lymph nodes with no ECS, or those with primary site adverse features were treated with radiation alone. Arm C included patients who had ECS in any lymph node and were treated with chemoradiation. The primary endpoint was quality of life at 1 year compared with a matched historical control. Results: Thirty-four patients were enrolled and underwent selective neck dissection. On the basis of pathologic characteristics, 14 patients were assigned to arm A, 10 patients to arm B, and 9 to arm C. A significant improvement was observed in Head and Neck Quality of Life (HNQOL) compared with historical controls (−2.6 vs. −11.9, P = 0.034). With a median follow-up of 37 months, the 3-year overall survival was 100% and estimated 3-year estimated progression-free survival was 96% [95% confidence interval (CI), 76%–99%]. Conclusions: A neck dissection–driven treatment paradigm warrants further research as a deintensification strategy.


3 June 2024
Verified
Other
Open access
PDF file
PSPaul L. Swiecicki
Paul L. Swiecicki
EBEmily Bellile
Emily Bellile
ADAleksandar F. Dragovic
Aleksandar F. Dragovic
JMJonathan McHugh
Jonathan McHugh
AUAaron Udager
Aaron Udager
MSMatthew E. Spector
Matthew E. Spector
Supplementary Table 2: Change in Stage with Neck Dissection

3 June 2024
Verified
Other
Open access
PDF file
PSPaul L. Swiecicki
Paul L. Swiecicki
EBEmily Bellile
Emily Bellile
ADAleksandar F. Dragovic
Aleksandar F. Dragovic
JMJonathan McHugh
Jonathan McHugh
AUAaron Udager
Aaron Udager
MSMatthew E. Spector
Matthew E. Spector
Supplemental Table 1: Representativeness of Study Participants

3 June 2024
Verified
Other
Open access
PDF file
PSPaul L. Swiecicki
Paul L. Swiecicki
EBEmily Bellile
Emily Bellile
ADAleksandar F. Dragovic
Aleksandar F. Dragovic
JMJonathan McHugh
Jonathan McHugh
AUAaron Udager
Aaron Udager
MSMatthew E. Spector
Matthew E. Spector
Supplementary Table 2: Change in Stage with Neck Dissection

3 June 2024
Verified
Other
Open access
PDF file
PSPaul L. Swiecicki
Paul L. Swiecicki
EBEmily Bellile
Emily Bellile
ADAleksandar F. Dragovic
Aleksandar F. Dragovic
JMJonathan McHugh
Jonathan McHugh
AUAaron Udager
Aaron Udager
MSMatthew E. Spector
Matthew E. Spector
Supplemental Table 1: Representativeness of Study Participants